The Real-World Clinical Outcomes of Heavily Pretreated HER2+ and HER2-Low Metastatic Breast Cancer Patients Treated with Trastuzumab Deruxtecan at a Single Centre

Background: Trastuzumab deruxtecan (TDXd) is an antibody–drug conjugate that has demonstrated impressive activity in randomized controlled clinical trials in the context of patients with HER2-amplified and HER2-low metastatic breast cancer. We aimed to review the activity and adverse event profile o...

Volledige beschrijving

Bibliografische gegevens

Hoofdauteurs:	Anna-Maria Lazaratos, Matthew Dankner, Aalya Hamouda, Soumaya Labidi, Victor Cohen, Lawrence Panasci, Jennifer E. Friedmann, François Patenaude, Cristiano Ferrario, Mark Basik, April A. N. Rose, Parvaneh Fallah
Formaat:	Artigo
Taal:	Inglês
Gepubliceerd in:	MDPI AG 2024-12-01
Reeks:	Current Oncology
Onderwerpen:	trastuzumab deruxtecan TDXd antibody–drug conjugate breast cancer
Online toegang:	https://www.mdpi.com/1718-7729/32/1/1
Tags:	Voeg label toe Geen labels, Wees de eerste die dit record labelt!